Everyone who needs a transplant deserves an optimal match.

At Pirche, we revolutionize transplant medicine and immunotherapy through cutting-edge technology and unparalleled precision.

Invest in the future of Health care.

Invest now in Pirche.
Why choose pirche

Precision

Epitope-level matching provides a finer degree of compatibility assessment over traditional HLA matching.

Reliability

Backed by extensive research in over 250,000 cases and >80 publications on clinical validation, PIRCHE has been validated across all solid-organ types and bone marrow transplantation.

Innovation

Our dedication to continual refinement of algorithms ensures our technology stays at the forefront of transplantation science and the clinician and the transplant patient receive world-class HLA risk assessments

Our partners

Transplant Medicine

Compatibility between a recipient and a donor is at the core of success in solid-organ and bone marrow transplantation.



PIRCHE focuses on predicting how well the recipient's immune system will recognize and respond to the donor organ based on HLA epitopes.

High complexity testing for HLA genes are utilized for donor-recipient matching, and understanding immune risk for each pair.

Minimize Graft versus Host Disease

Guiding immunosuppressive therapy

Optimizing biomarker monitoring

Donor selection

Technology

TxPredictor

Our state-of-the-art platform, TxPredictor, merges genetic typing with real-time, AI-supported immunological simulations, enabling clinicians to make precise, personalized medical decisions.

The Pirche TxPredictor platform uses T and B cell epitope predictors, allowing clinicians and laboratories to interact with their patient’s tissue compatibility data like never before. Running on a high-performance cloud infrastructure, it combines real time analysis with clear user interfaces.


By leveraging standard clinical lab results and seamlessly integrating with leading laboratory IT systems, we provide a plug-and-play solution that transforms patient care.

Highlights & features

Absolute and relative immunologic risk quantification

Low resolution HLA typing support

Real time & cloud based

Low turnaround time

Integration with major HLA vendors’ software

No maintenance

Cell Therapy

PIRCHE epitope matching reduces the risk of immune rejection, by identifying donors whose cells are less likely to be recognised as foreign. This is crucial in allogeneic cell therapy where mismatched donor cells can lead to immune-mediated destruction of the therapeutic cells.

Pirche can help

Identify optimal
‘off-the-shelf’ therapy

Minimize Graft versus Host Disease

Optimize therapy efficacy and safety